Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Madrigal Pharmaceuticals' Rezdiffra has received a positive recommendation from the European Medicines Agency's CHMP for treating adults with noncirrhotic MASH and moderate to advanced fibrosis, potentially making it the first approved medication in the E.U. for this condition. A final decision from the European Commission is expected in August, following the FDA's accelerated approval in the U.S. in March 2024, where Rezdiffra generated over $137 million in first-quarter 2025 sales.

Analysis

Madrigal Pharmaceuticals (MDGL) has achieved a significant regulatory milestone with its Rezdiffra treatment for adults with noncirrhotic MASH and moderate to advanced fibrosis, as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended its approval. This positive opinion positions Rezdiffra to potentially become the first medication approved in the E.U. for MASH, a condition noted as the fastest-growing indication for liver transplantation in Europe, highlighting a substantial unmet medical need and considerable market opportunity. A final decision from the European Commission, which generally follows CHMP advice, is anticipated in August. This European progress follows the U.S. Food and Drug Administration's accelerated approval of Rezdiffra in March 2024, after which the drug demonstrated robust initial commercial traction, generating sales exceeding $137 million in the first quarter of 2025.

Key Decisions for Investors

• The CHMP's positive recommendation significantly enhances the probability of Rezdiffra's approval in the E.U., potentially granting Madrigal a first-mover advantage in a key market with high unmet demand for MASH treatments.
• Investors should closely monitor the final European Commission decision expected in August, as approval would represent a major catalyst for Madrigal, further validating Rezdiffra's commercial prospects demonstrated by its strong U.S. launch sales.
• Given the positive regulatory outlook in Europe and strong early U.S. sales figures, investors may consider the potential for accelerated revenue growth for Madrigal, though the final E.U. decision remains a key event to watch.